Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 87 entries
Sorted by: Best Match Show Resources per page
Erratum.

Journal of viral hepatitis

[No authors listed]
PMID: 27641615
J Viral Hepat. 2016 Oct;23(10):833. doi: 10.1111/jvh.12569.

No abstract available.

Cite
Erratum. J Viral Hepat. 2016;23(10):833doi: 10.1111/jvh.12569.
(2016). Erratum. Journal of viral hepatitis, 23(10), 833. https://doi.org/10.1111/jvh.12569
"Erratum." Journal of viral hepatitis vol. 23,10 (2016): 833. doi: https://doi.org/10.1111/jvh.12569
Erratum. J Viral Hepat. 2016 Oct;23(10):833. doi: 10.1111/jvh.12569. PMID: 27641615.
Copy Download .nbib Format: NLM
Comments on: The role of caesarean section and nonbreastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg- and HBeAg-positive mothers: Results from a prospective cohort study and a meta-analysis.

Journal of viral hepatitis

Zhang Y, Yang M, Huang X, Yang H.
PMID: 34997998
J Viral Hepat. 2022 Jan 08; doi: 10.1111/jvh.13641. Epub 2022 Jan 08.

No abstract available.

Cite
Zhang Y, Yang M, Huang X, et al. Comments on: The role of caesarean section and nonbreastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg- and HBeAg-positive mothers: Results from a prospective cohort study and a meta-analysis. J Viral Hepat. 2022;doi: 10.1111/jvh.13641.
Zhang, Y., Yang, M., Huang, X., & Yang, H. (2022). Comments on: The role of caesarean section and nonbreastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg- and HBeAg-positive mothers: Results from a prospective cohort study and a meta-analysis. Journal of viral hepatitis, . https://doi.org/10.1111/jvh.13641
Zhang, Yanmei, et al. "Comments on: The role of caesarean section and nonbreastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg- and HBeAg-positive mothers: Results from a prospective cohort study and a meta-analysis." Journal of viral hepatitis vol. (2022). doi: https://doi.org/10.1111/jvh.13641
Zhang Y, Yang M, Huang X, Yang H. Comments on: The role of caesarean section and nonbreastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg- and HBeAg-positive mothers: Results from a prospective cohort study and a meta-analysis. J Viral Hepat. 2022 Jan 08; doi: 10.1111/jvh.13641. Epub 2022 Jan 08. PMID: 34997998.
Copy Download .nbib Format: NLM
Neuropsychological effects of direct-acting antiviral treatment for Hepatitis C virus subjects: A systematic review.

Journal of viral hepatitis

Santos-Lima C, Souza-Marques B, Vieira F, Isabel Schinoni M, Quarantini LC, Abreu N.
PMID: 34320255
J Viral Hepat. 2021 Dec;28(12):1672-1682. doi: 10.1111/jvh.13584. Epub 2021 Aug 12.

Direct-acting antivirals (DAAs) have been approved in recent years to treat patients infected by the Hepatitis C virus (HCV). The DAAs treatment is well tolerated and increases sustained virological responses, but there is no consensus about the neuropsychological functioning...

Cite
Santos-Lima C, Souza-Marques B, Vieira F, et al. Neuropsychological effects of direct-acting antiviral treatment for Hepatitis C virus subjects: A systematic review. J Viral Hepat. 2021;28(12):1672-1682doi: 10.1111/jvh.13584.
Santos-Lima, C., Souza-Marques, B., Vieira, F., Isabel Schinoni, M., Quarantini, L. C., & Abreu, N. (2021). Neuropsychological effects of direct-acting antiviral treatment for Hepatitis C virus subjects: A systematic review. Journal of viral hepatitis, 28(12), 1672-1682. https://doi.org/10.1111/jvh.13584
Santos-Lima, Cassio, et al. "Neuropsychological effects of direct-acting antiviral treatment for Hepatitis C virus subjects: A systematic review." Journal of viral hepatitis vol. 28,12 (2021): 1672-1682. doi: https://doi.org/10.1111/jvh.13584
Santos-Lima C, Souza-Marques B, Vieira F, Isabel Schinoni M, Quarantini LC, Abreu N. Neuropsychological effects of direct-acting antiviral treatment for Hepatitis C virus subjects: A systematic review. J Viral Hepat. 2021 Dec;28(12):1672-1682. doi: 10.1111/jvh.13584. Epub 2021 Aug 12. PMID: 34320255.
Copy Download .nbib Format: NLM
CORRIGENDUM.

Journal of viral hepatitis

[No authors listed]
PMID: 34784089
J Viral Hepat. 2021 Dec;28(12):1767. doi: 10.1111/jvh.13624.

No abstract available.

Cite
CORRIGENDUM. J Viral Hepat. 2021;28(12):1767doi: 10.1111/jvh.13624.
(2021). CORRIGENDUM. Journal of viral hepatitis, 28(12), 1767. https://doi.org/10.1111/jvh.13624
"CORRIGENDUM." Journal of viral hepatitis vol. 28,12 (2021): 1767. doi: https://doi.org/10.1111/jvh.13624
CORRIGENDUM. J Viral Hepat. 2021 Dec;28(12):1767. doi: 10.1111/jvh.13624. PMID: 34784089.
Copy Download .nbib Format: NLM
Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment.

Journal of viral hepatitis

Ikenaga H, Uchida-Kobayashi S, Tamori A, Odagiri N, Yoshida K, Kotani K, Motoyama H, Kozuka R, Kawamura E, Hagihara A, Fujii H, Enomoto M, Kawada N.
PMID: 34695288
J Viral Hepat. 2021 Oct 25; doi: 10.1111/jvh.13627. Epub 2021 Oct 25.

Hepatocellular carcinoma (HCC) has high recurrence rates. HCC sometimes progresses from early-stage HCC (Barcelona Clinic Liver Cancer [BCLC] stage 0/A) to advanced-stage HCC after repeated recurrences and treatments. HCC progression deteriorates quality of life and prognosis. However, the effect...

Cite
Ikenaga H, Uchida-Kobayashi S, Tamori A, et al. Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. J Viral Hepat. 2021;doi: 10.1111/jvh.13627.
Ikenaga, H., Uchida-Kobayashi, S., Tamori, A., Odagiri, N., Yoshida, K., Kotani, K., Motoyama, H., Kozuka, R., Kawamura, E., Hagihara, A., Fujii, H., Enomoto, M., & Kawada, N. (2021). Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. Journal of viral hepatitis, . https://doi.org/10.1111/jvh.13627
Ikenaga, Hiroko, et al. "Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment." Journal of viral hepatitis vol. (2021). doi: https://doi.org/10.1111/jvh.13627
Ikenaga H, Uchida-Kobayashi S, Tamori A, Odagiri N, Yoshida K, Kotani K, Motoyama H, Kozuka R, Kawamura E, Hagihara A, Fujii H, Enomoto M, Kawada N. Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. J Viral Hepat. 2021 Oct 25; doi: 10.1111/jvh.13627. Epub 2021 Oct 25. PMID: 34695288.
Copy Download .nbib Format: NLM
Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States.

Journal of viral hepatitis

Zhou Y, Li J, Gordon SC, Trudeau S, Rupp LB, Boscarino JA, Daida YG, Schmidt MA, Lu M.
PMID: 34905259
J Viral Hepat. 2021 Dec 14; doi: 10.1111/jvh.13639. Epub 2021 Dec 14.

We investigated factors associated with rates of recommended monitoring of chronic hepatitis B (HBV) patients for viral DNA and alanine aminotransferase (ALT), and initiation of antiviral treatment among eligible patients, in a US cohort of patients under routine care....

Cite
Zhou Y, Li J, Gordon SC, et al. Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States. J Viral Hepat. 2021;doi: 10.1111/jvh.13639.
Zhou, Y., Li, J., Gordon, S. C., Trudeau, S., Rupp, L. B., Boscarino, J. A., Daida, Y. G., Schmidt, M. A., & Lu, M. (2021). Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States. Journal of viral hepatitis, . https://doi.org/10.1111/jvh.13639
Zhou, Yueren, et al. "Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States." Journal of viral hepatitis vol. (2021). doi: https://doi.org/10.1111/jvh.13639
Zhou Y, Li J, Gordon SC, Trudeau S, Rupp LB, Boscarino JA, Daida YG, Schmidt MA, Lu M. Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States. J Viral Hepat. 2021 Dec 14; doi: 10.1111/jvh.13639. Epub 2021 Dec 14. PMID: 34905259.
Copy Download .nbib Format: NLM
A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.

Journal of viral hepatitis

Palmer AY, Chan K, Gold J, Layton C, Elsum I, Hellard M, Stoove M, Doyle JS, Pedrana A, Scott N.
PMID: 34415639
J Viral Hepat. 2021 Nov;28(11):1624-1634. doi: 10.1111/jvh.13596. Epub 2021 Aug 28.

Financial incentives may reduce opportunity costs associated with people who become lost to follow-up in hepatitis C treatment programs. We estimated the impact that different financial incentive amounts would need to have on retention in care to maintain the...

Cite
Palmer AY, Chan K, Gold J, et al. A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign. J Viral Hepat. 2021;28(11):1624-1634doi: 10.1111/jvh.13596.
Palmer, A. Y., Chan, K., Gold, J., Layton, C., Elsum, I., Hellard, M., Stoove, M., Doyle, J. S., Pedrana, A., Scott, N. (2021). A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign. Journal of viral hepatitis, 28(11), 1624-1634. https://doi.org/10.1111/jvh.13596
Palmer, Anna Y, et al. "A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign." Journal of viral hepatitis vol. 28,11 (2021): 1624-1634. doi: https://doi.org/10.1111/jvh.13596
Palmer AY, Chan K, Gold J, Layton C, Elsum I, Hellard M, Stoove M, Doyle JS, Pedrana A, Scott N. A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign. J Viral Hepat. 2021 Nov;28(11):1624-1634. doi: 10.1111/jvh.13596. Epub 2021 Aug 28. PMID: 34415639.
Copy Download .nbib Format: NLM
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.

Journal of viral hepatitis

Gane E, de Ledinghen V, Dylla DE, Rizzardini G, Shiffman ML, Barclay ST, Calleja JL, Xue Z, Burroughs M, Gutierrez JA.
PMID: 34448313
J Viral Hepat. 2021 Nov;28(11):1635-1642. doi: 10.1111/jvh.13600. Epub 2021 Sep 08.

Sustained virologic response at posttreatment Week 12 (SVR12) is the widely accepted efficacy endpoint for direct-acting antiviral agents. Those with hepatitis C virus (HCV) are presenting younger with milder liver disease, potentially reducing need for long-term liver posttreatment monitoring....

Cite
Gane E, de Ledinghen V, Dylla DE, et al. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. J Viral Hepat. 2021;28(11):1635-1642doi: 10.1111/jvh.13600.
Gane, E., de Ledinghen, V., Dylla, D. E., Rizzardini, G., Shiffman, M. L., Barclay, S. T., Calleja, J. L., Xue, Z., Burroughs, M., & Gutierrez, J. A. (2021). Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. Journal of viral hepatitis, 28(11), 1635-1642. https://doi.org/10.1111/jvh.13600
Gane, Edward, et al. "Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials." Journal of viral hepatitis vol. 28,11 (2021): 1635-1642. doi: https://doi.org/10.1111/jvh.13600
Gane E, de Ledinghen V, Dylla DE, Rizzardini G, Shiffman ML, Barclay ST, Calleja JL, Xue Z, Burroughs M, Gutierrez JA. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. J Viral Hepat. 2021 Nov;28(11):1635-1642. doi: 10.1111/jvh.13600. Epub 2021 Sep 08. PMID: 34448313.
Copy Download .nbib Format: NLM
Long-term benefits of interferon-α therapy in children with HBeAg-positive immune-active chronic hepatitis B.

Journal of viral hepatitis

Wang L, Zhao J, Liu J, Zhen C, Zhang M, Dong Y, Gan Y, Xu Z, Li Y, Zhu S, Wang FS.
PMID: 34448324
J Viral Hepat. 2021 Nov;28(11):1554-1562. doi: 10.1111/jvh.13598. Epub 2021 Sep 03.

The long-term benefits of interferon-α (IFN-α) treatment in children with chronic hepatitis B (CHB) remain unclear. We conducted a retrospective and real-world study to evaluate the safety and long-term clearance rates of hepatitis B e antigen (HBeAg) and hepatitis...

Cite
Wang L, Zhao J, Liu J, et al. Long-term benefits of interferon-α therapy in children with HBeAg-positive immune-active chronic hepatitis B. J Viral Hepat. 2021;28(11):1554-1562doi: 10.1111/jvh.13598.
Wang, L., Zhao, J., Liu, J., Zhen, C., Zhang, M., Dong, Y., Gan, Y., Xu, Z., Li, Y., Zhu, S., & Wang, F. S. (2021). Long-term benefits of interferon-α therapy in children with HBeAg-positive immune-active chronic hepatitis B. Journal of viral hepatitis, 28(11), 1554-1562. https://doi.org/10.1111/jvh.13598
Wang, Limin, et al. "Long-term benefits of interferon-α therapy in children with HBeAg-positive immune-active chronic hepatitis B." Journal of viral hepatitis vol. 28,11 (2021): 1554-1562. doi: https://doi.org/10.1111/jvh.13598
Wang L, Zhao J, Liu J, Zhen C, Zhang M, Dong Y, Gan Y, Xu Z, Li Y, Zhu S, Wang FS. Long-term benefits of interferon-α therapy in children with HBeAg-positive immune-active chronic hepatitis B. J Viral Hepat. 2021 Nov;28(11):1554-1562. doi: 10.1111/jvh.13598. Epub 2021 Sep 03. PMID: 34448324.
Copy Download .nbib Format: NLM
Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: A cohort study.

Journal of viral hepatitis

Coppola C, Masarone M, Bartoli M, Staiano L, Coppola R, Torre P, Conforti M, Amoruso D, Gardini I, Persico M.
PMID: 34585821
J Viral Hepat. 2021 Sep 29; doi: 10.1111/jvh.13623. Epub 2021 Sep 29.

No abstract available.

Cite
Coppola C, Masarone M, Bartoli M, et al. Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: A cohort study. J Viral Hepat. 2021;doi: 10.1111/jvh.13623.
Coppola, C., Masarone, M., Bartoli, M., Staiano, L., Coppola, R., Torre, P., Conforti, M., Amoruso, D., Gardini, I., & Persico, M. (2021). Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: A cohort study. Journal of viral hepatitis, . https://doi.org/10.1111/jvh.13623
Coppola, Carmine, et al. "Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: A cohort study." Journal of viral hepatitis vol. (2021). doi: https://doi.org/10.1111/jvh.13623
Coppola C, Masarone M, Bartoli M, Staiano L, Coppola R, Torre P, Conforti M, Amoruso D, Gardini I, Persico M. Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: A cohort study. J Viral Hepat. 2021 Sep 29; doi: 10.1111/jvh.13623. Epub 2021 Sep 29. PMID: 34585821; PMCID: PMC8662270.
Copy Download .nbib Format: NLM
Efficacy of an eConsult service to cure hepatitis C in primary care.

Journal of viral hepatitis

Nishiguchi J, McNamara A, Surlyn CS, Eagen KV, Feeney L, Lian V, Smith DE.
PMID: 34586710
J Viral Hepat. 2021 Sep 29; doi: 10.1111/jvh.13616. Epub 2021 Sep 29.

In 2016, an eConsult service was developed within a safety net health system to expand access to hepatitis C (HCV) treatment in the primary care setting. The eConsult system provides individualized treatment recommendations from specially trained primary care pharmacists...

Cite
Nishiguchi J, McNamara A, Surlyn CS, et al. Efficacy of an eConsult service to cure hepatitis C in primary care. J Viral Hepat. 2021;doi: 10.1111/jvh.13616.
Nishiguchi, J., McNamara, A., Surlyn, C. S., Eagen, K. V., Feeney, L., Lian, V., & Smith, D. E. (2021). Efficacy of an eConsult service to cure hepatitis C in primary care. Journal of viral hepatitis, . https://doi.org/10.1111/jvh.13616
Nishiguchi, Jacey, et al. "Efficacy of an eConsult service to cure hepatitis C in primary care." Journal of viral hepatitis vol. (2021). doi: https://doi.org/10.1111/jvh.13616
Nishiguchi J, McNamara A, Surlyn CS, Eagen KV, Feeney L, Lian V, Smith DE. Efficacy of an eConsult service to cure hepatitis C in primary care. J Viral Hepat. 2021 Sep 29; doi: 10.1111/jvh.13616. Epub 2021 Sep 29. PMID: 34586710.
Copy Download .nbib Format: NLM
Hepatitis C virus care cascade in persons experiencing homelessness in the United States in the era of direct-acting antiviral agents: A scoping review.

Journal of viral hepatitis

Del Rosario A, Eldredge JD, Doorley S, Mishra SI, Kesler D, Page K.
PMID: 34314081
J Viral Hepat. 2021 Nov;28(11):1506-1514. doi: 10.1111/jvh.13583. Epub 2021 Aug 11.

The hepatitis C virus (HCV) care cascade has been well characterized in the general United States population and other subpopulations since curative medications have been available. However, information is limited on care cascade outcomes in persons experiencing homelessness. The...

Cite
Del Rosario A, Eldredge JD, Doorley S, et al. Hepatitis C virus care cascade in persons experiencing homelessness in the United States in the era of direct-acting antiviral agents: A scoping review. J Viral Hepat. 2021;28(11):1506-1514doi: 10.1111/jvh.13583.
Del Rosario, A., Eldredge, J. D., Doorley, S., Mishra, S. I., Kesler, D., & Page, K. (2021). Hepatitis C virus care cascade in persons experiencing homelessness in the United States in the era of direct-acting antiviral agents: A scoping review. Journal of viral hepatitis, 28(11), 1506-1514. https://doi.org/10.1111/jvh.13583
Del Rosario, Aubrey, et al. "Hepatitis C virus care cascade in persons experiencing homelessness in the United States in the era of direct-acting antiviral agents: A scoping review." Journal of viral hepatitis vol. 28,11 (2021): 1506-1514. doi: https://doi.org/10.1111/jvh.13583
Del Rosario A, Eldredge JD, Doorley S, Mishra SI, Kesler D, Page K. Hepatitis C virus care cascade in persons experiencing homelessness in the United States in the era of direct-acting antiviral agents: A scoping review. J Viral Hepat. 2021 Nov;28(11):1506-1514. doi: 10.1111/jvh.13583. Epub 2021 Aug 11. PMID: 34314081.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 87 entries